CDK9

SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022

Retrieved on: 
Wednesday, November 2, 2022
Lymphatic system, MD, WT1, CEO, Cancer, Baylor University Medical Center, Clinical trial, SLS, GLOBE, Research, Memorial Sloan Kettering Cancer Center, Drug, NASDAQ, Company, Patient, Acute myeloid leukemia, Doctor of Science, Senior, GPS, Therapy, CDK9, Pharmaceutical industry, Greater China

NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (SELLAS or the Company), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provides webcast information for its virtual investor event on November 14, 2022, at 8:30 a.m.

Key Points: 
  • NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (SELLAS or the Company), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provides webcast information for its virtual investor event on November 14, 2022, at 8:30 a.m.
  • at which the Company will provide an update on its Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia.
  • To attend the live video webcast, please register or email KCSA Strategic Communications at [email protected] .
  • About SELLAS Life Sciences Group, Inc.
    SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.

Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022

Retrieved on: 
Wednesday, October 26, 2022
Company, National University Hospital, MYC, Endometrial cancer, City of Hope National Medical Center, Safety, Cyclin E, CTD, Lymphatic system, Hematology, RNAP, HER2, CDK, CR, Cyclin, Risk, BCL2, CLL, Trastuzumab, Breast cancer, Uterine serous carcinoma, Cyclin-dependent kinase, CDK9, RNA, Annual report, Phosphorylation, Patient, Multiple myeloma, NCT, MCL1, CCNE, ALL, News, Adult, Research, COVID-19, Lymphoma, PLK1, FDA, B-cell lymphoma, RNA polymerase II, CDK2, AML, Ovarian cancer, All rights reserved, Cell cycle, Gene, Neuroblastoma, MD Anderson Cancer Center, Cyclacel, Pharmaceutical industry

Fadraciclib, a next generation CDK inhibitor, is a highly selective, potent, orally and intravenously available, inhibitor of CDK2 and CDK9.

Key Points: 
  • Fadraciclib, a next generation CDK inhibitor, is a highly selective, potent, orally and intravenously available, inhibitor of CDK2 and CDK9.
  • By inhibiting CDK2 and CDK9 fadraciclib causes apoptotic death of cancer cells at sub-micromolar concentrations.
  • Fadraciclib is being tested in a Phase 1/2 trial for the treatment of advanced solid tumors and lymphoma (065-101; NCT#04983810 ) and a Phase 1/2 trial for the treatment of hematological malignancies (065-102; NCT#05168904 ).
  • In a prior Phase 1 open-label trial (CYC065-01), patients with high copy CCNE (cyclin E), MYC or MCL1 showed sensitivity to intravenously administered, single-agent fadraciclib.

Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

Retrieved on: 
Tuesday, October 18, 2022
U.S. Securities and Exchange Commission, Population, PRMT5, PRT, Family, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Biotechnology, BRG1, RNA, Security (finance), Cell, Technology, Private Securities Litigation Reform Act, Food, Goal, NSCLC, Cell death, Large-cell lung carcinoma, Pharmacokinetics, SMARCA2, Safety, CDK9, Survival, GLOBE, Brain, Forward-looking statement, DNA, BRM, FDA, COVID-19, MCL1, Prelude, Cancer, Risk, Pharmaceutical industry, Vaccine, IND, SMARCA4

Preclinical models with SMARCA4 deletions demonstrated that selective degradation of SMARCA2 with our potent and highly selective molecule PRT3789, resulted in significant anti-tumor activity at well tolerated doses, said Dr. Peggy Scherle, Chief Scientific Officer of Prelude.

Key Points: 
  • Preclinical models with SMARCA4 deletions demonstrated that selective degradation of SMARCA2 with our potent and highly selective molecule PRT3789, resulted in significant anti-tumor activity at well tolerated doses, said Dr. Peggy Scherle, Chief Scientific Officer of Prelude.
  • Historically, structural similarities between members of the SMARCA family have made it challenging to selectively inhibit SMARCA2.
  • Clearance of the IND for PRT3789 represents a major milestone for Prelude Therapeutics, as we advance our first-in-class SMARCA2 protein degrader from discovery to the clinic.
  • Preludes pipeline includes five candidates currently in clinical development: PRT811, a highly selective, potent, orally bioavailable PRMT5 inhibitor; PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645, a brain penetrant CDK4/6 inhibitor, and PRT3789, a SMARCA2/BRM protein degrader.

SELLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022

Retrieved on: 
Monday, October 17, 2022
Lymphatic system, Memorial Sloan Kettering Cancer Center, Baylor University Medical Center, Therapy, SLS, Acute myeloid leukemia, AML, Drug, NASDAQ, Patient, GPS, Doctor of Science, WT1, Cancer, Senior, Company, MD, CEO, Research, GLOBE, Clinical trial, CDK9, Pharmaceutical industry, Greater China

Further details regarding how to access the update call will be provided in the coming weeks.

Key Points: 
  • Further details regarding how to access the update call will be provided in the coming weeks.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
  • SELLAS lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.
  • GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications.

Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium

Retrieved on: 
Thursday, October 13, 2022
Cyclin E, News, RNAP, PLK1, Risk, CLL, All rights reserved, AML, Lymphoma, Multiple myeloma, Annual report, Patient, Neuroblastoma, Cyclacel, Research, RNA, CDK2, CR, B-cell lymphoma, HER2, Endometrial cancer, RNA polymerase II, Cyclin-dependent kinase, Company, Trastuzumab, Phosphorylation, CCNE, Breast cancer, Uterine serous carcinoma, Adult, Safety, MYC, BCL2, CDK9, Lymphatic system, Hematology, Cell cycle, ALL, FDA, COVID-19, CDK, NCT, MCL1, Gene, Ovarian cancer, CTD, Pharmaceutical industry

Fadraciclib, a next generation CDK inhibitor, is a highly selective, potent, orally and intravenously available, inhibitor of CDK2 and CDK9.

Key Points: 
  • Fadraciclib, a next generation CDK inhibitor, is a highly selective, potent, orally and intravenously available, inhibitor of CDK2 and CDK9.
  • Fadraciclib is being tested in a Phase 1/2 trial for the treatment of advanced solid tumors and lymphoma (065-101; NCT#04983810 ) and a Phase 1/2 trial for the treatment of hematological malignancies (065-102; NCT#05168904 ).
  • In a prior Phase 1 open-label trial (CYC065-01), patients with high copy CCNE (cyclin E), MYC or MCL1 showed sensitivity to intravenously administered, single-agent fadraciclib.
  • The Cyclacel logo and Cyclacel are trademarks of Cyclacel Pharmaceuticals, Inc.

Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022

Retrieved on: 
Wednesday, October 12, 2022
SAN, LinkedIn, SYK, U.S. Securities and Exchange Commission, Alveolar rhabdomyosarcoma, Therapy, Risk, SEC, Growth, Acute myeloid leukemia, The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, AML, ARMS, Neoplasm, Patient, Research, Security (finance), PDX, Nasdaq, Cancer, Private Securities Litigation Reform Act, Breast, EORTC, MYC, CDK9, GLOBE, SMM, Forward-looking statement, COVID-19, KRON, Poster, Pharmaceutical industry, Kronos

The poster will include preclinical data demonstrating that Kronos Bios internally discovered oral CDK9 inhibitor, KB-0742 induced regressions in a preclinical model of MYCN-amplified neuroblastoma tumors and inhibited growth in patient-derived xenograft (PDX) models of transcriptionally addicted Ewing sarcoma (EW) and alveolar rhabdomyosarcoma (ARMS).

Key Points: 
  • The poster will include preclinical data demonstrating that Kronos Bios internally discovered oral CDK9 inhibitor, KB-0742 induced regressions in a preclinical model of MYCN-amplified neuroblastoma tumors and inhibited growth in patient-derived xenograft (PDX) models of transcriptionally addicted Ewing sarcoma (EW) and alveolar rhabdomyosarcoma (ARMS).
  • This is the first preclinical analysis to support the investigational compounds potential in pediatric tumors.
  • Kronos Bio remains on track to provide an update on the study, including the Recommended Phase 2 Dose (RP2D) in the fourth quarter.
  • Kronos Bio is a biopharmaceutical company that is advancing three investigational compounds in clinical trials for patients with cancer.

SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S

Retrieved on: 
Tuesday, October 11, 2022
Quality of life, Memorial Sloan Kettering Cancer Center, Therapy, SEC, SLS, Acute myeloid leukemia, Multiple myeloma, Annual report, NASDAQ, Patient, 3D, Drug development, Medication, GPS, Doctor of Science, WT1, Cancer, Company, MD, GLOBE, CDK9, Terminology, COVID-19, Conditional sentence, Pharmaceutical industry, Greater China

The dosing of the first patient in 3D Medicines Phase 1 clinical trial for GPS, or 3D189, in China, marks an important milestone for GPS global clinical development.

Key Points: 
  • The dosing of the first patient in 3D Medicines Phase 1 clinical trial for GPS, or 3D189, in China, marks an important milestone for GPS global clinical development.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
  • 3D Medicines Inc. is a commercial-stage biopharmaceutical company with a mission to help people with cancer live longer and better.
  • These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties.

SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations

Retrieved on: 
Thursday, September 29, 2022
Bioequivalence, Therapy, PK, WT1, Sex, COVID-19, MD, SLS, Â, Society, NEW, Company, Senior, SOHO, PH, Patient, Memorial Sloan Kettering Cancer Center, Hematology-Oncology and Stem Cell Transplantation Research Center, Terminology, Annual report, Cyclin-dependent kinase 9, Drug development, NASDAQ, GLOBE, SEC, Lymphoma, Drug, Rat, GPS, CDK9, Human, Pharmaceutical industry, Greater China

The bioequivalence study was performed to evaluate the effect of different formulations on GFH009s preclinical pharmacokinetic (PK) profile.

Key Points: 
  • The bioequivalence study was performed to evaluate the effect of different formulations on GFH009s preclinical pharmacokinetic (PK) profile.
  • Dr. Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS, presented the findings at this years Meeting of the Society of Hematologic Oncology (SOHO) in a poster titled Pharmacokinetics and Bioequivalence of Two Formulations of GFH009 Maleate Injection in Sprague Dawley Rats.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
  • These statements include, without limitation, statements related to preclinical data for GFH009, plans for further development of GFH009, and the potential for GFH009 as a drug development candidate.

SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting

Retrieved on: 
Thursday, September 22, 2022
Therapy, WT1, The Year's Best Science Fiction: Tenth Annual Collection, COVID-19, SLS, Company, SOHO, Memorial Sloan Kettering Cancer Center, Hematology-Oncology and Stem Cell Transplantation Research Center, Terminology, Annual report, Drug development, NASDAQ, GLOBE, SEC, CDK9, GPS, Society, Pharmaceutical industry, Greater China

The poster presentation characterizes the preclinical pharmacokinetic (PK) profiles of two different formulations of GFH009 maleate, pH 4.5 and pH 6.0.

Key Points: 
  • The poster presentation characterizes the preclinical pharmacokinetic (PK) profiles of two different formulations of GFH009 maleate, pH 4.5 and pH 6.0.
  • Additional presentation details can be found below:
    About SELLAS Life Sciences Group, Inc.
    SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
  • SELLAS lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.
  • GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications.

SELLAS Life Sciences to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th

Retrieved on: 
Wednesday, September 14, 2022
Therapy, WT1, COVID-19, Doctor of Science, Lotte New York Palace Hotel, MD, SLS, Company, Private Securities Litigation Reform Act, Memorial Sloan Kettering Cancer Center, Cantor, Annual report, NASDAQ, Conference, GLOBE, SEC, CDK9, GPS, Pharmaceutical industry, Hematology, Greater China

h.c, President and Chief Executive Officer of SELLAS, will participate in the Cantor Oncology, Hematology, HemeOnc Conference to be held at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.

Key Points: 
  • h.c, President and Chief Executive Officer of SELLAS, will participate in the Cantor Oncology, Hematology, HemeOnc Conference to be held at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.
  • Dr. Stergiou will participate in the Leukemia and MDS panel at 3:25 p.m. Eastern Time.
  • For more information about the conference, or to schedule a one-on-one meeting with SELLAS management, please contact your Cantor representative directly, or send an email to KCSA Strategic Communications at [email protected] .
  • About SELLAS Life Sciences Group, Inc.
    SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.